Azacitidine
HVA Regimen
Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HVA Regimen cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Venetoclax Nanfang Hospital, Southern Medical University | Phase 2 | B |
Hht Nanfang Hospital, Southern Medical University | Phase 2 | B |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →